JP2024167313A5 - - Google Patents

Download PDF

Info

Publication number
JP2024167313A5
JP2024167313A5 JP2024146208A JP2024146208A JP2024167313A5 JP 2024167313 A5 JP2024167313 A5 JP 2024167313A5 JP 2024146208 A JP2024146208 A JP 2024146208A JP 2024146208 A JP2024146208 A JP 2024146208A JP 2024167313 A5 JP2024167313 A5 JP 2024167313A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024146208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024167313A (ja
JP7854016B2 (ja
Filing date
Publication date
Priority claimed from JP2021562118A external-priority patent/JP2022529703A/ja
Application filed filed Critical
Publication of JP2024167313A publication Critical patent/JP2024167313A/ja
Publication of JP2024167313A5 publication Critical patent/JP2024167313A5/ja
Application granted granted Critical
Publication of JP7854016B2 publication Critical patent/JP7854016B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024146208A 2019-04-19 2024-08-28 腫瘍治療薬及びその応用 Active JP7854016B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910315634.9 2019-04-19
CN201910315634 2019-04-19
JP2021562118A JP2022529703A (ja) 2019-04-19 2020-04-15 腫瘍治療薬及びその応用
PCT/CN2020/084991 WO2020211792A1 (zh) 2019-04-19 2020-04-15 肿瘤治疗剂及其应用
JP2023129054A JP7547581B2 (ja) 2019-04-19 2023-08-08 腫瘍治療薬及びその応用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023129054A Division JP7547581B2 (ja) 2019-04-19 2023-08-08 腫瘍治療薬及びその応用

Publications (3)

Publication Number Publication Date
JP2024167313A JP2024167313A (ja) 2024-12-03
JP2024167313A5 true JP2024167313A5 (cg-RX-API-DMAC7.html) 2025-04-17
JP7854016B2 JP7854016B2 (ja) 2026-04-30

Family

ID=72837018

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021562118A Pending JP2022529703A (ja) 2019-04-19 2020-04-15 腫瘍治療薬及びその応用
JP2023129054A Active JP7547581B2 (ja) 2019-04-19 2023-08-08 腫瘍治療薬及びその応用
JP2024146208A Active JP7854016B2 (ja) 2019-04-19 2024-08-28 腫瘍治療薬及びその応用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2021562118A Pending JP2022529703A (ja) 2019-04-19 2020-04-15 腫瘍治療薬及びその応用
JP2023129054A Active JP7547581B2 (ja) 2019-04-19 2023-08-08 腫瘍治療薬及びその応用

Country Status (5)

Country Link
US (1) US12655199B2 (cg-RX-API-DMAC7.html)
EP (1) EP3960766A4 (cg-RX-API-DMAC7.html)
JP (3) JP2022529703A (cg-RX-API-DMAC7.html)
CN (2) CN119613553A (cg-RX-API-DMAC7.html)
WO (1) WO2020211792A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7840511B2 (ja) 2019-02-01 2026-04-06 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 抗クローディン18抗体及びそれらの使用の方法
CN114366818B (zh) * 2020-10-15 2025-02-25 上海美雅珂生物技术有限责任公司 抗体药物偶联物及其应用
WO2022206975A1 (zh) * 2021-04-02 2022-10-06 原启生物科技(上海)有限责任公司 Cldn18.2抗原结合蛋白及其用途
WO2023078386A1 (zh) 2021-11-05 2023-05-11 正大天晴药业集团股份有限公司 抗cldn18.2抗体及其用途
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
TW202535476A (zh) 2023-10-27 2025-09-16 大陸商康諾亞生物醫藥科技(成都)有限公司 使用抗密連蛋白18.2 adc之癌症治療
WO2025086268A1 (en) 2023-10-27 2025-05-01 Keymed Biosciences (Chengdu) Co., Ltd. Cancer treatment with anti-claudin 18.2 adc
AU2023470621A1 (en) 2023-10-27 2026-04-30 Keymed Biosciences Co., Ltd Cancer treatment with anti-claudin 18.2 adc
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026125345A1 (en) 2024-12-09 2026-06-18 Astrazeneca Ab Biliary tract cancer treatment with anti-claudin 18.2 adc
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
IL282953B2 (en) 2012-11-13 2026-02-01 Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh Agents for the treatment of claudin-expressing cancers
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2018006882A1 (zh) 2016-07-08 2018-01-11 科济生物医药(上海)有限公司 抗密蛋白18a2的抗体及其应用

Similar Documents

Publication Publication Date Title
JP2024045121A5 (cg-RX-API-DMAC7.html)
JP2025111463A5 (cg-RX-API-DMAC7.html)
JP2022061992A5 (cg-RX-API-DMAC7.html)
JP2023081303A5 (cg-RX-API-DMAC7.html)
JP2025032102A5 (cg-RX-API-DMAC7.html)
JP2020528768A5 (cg-RX-API-DMAC7.html)
JP2011509245A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2022530404A5 (cg-RX-API-DMAC7.html)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
JP2018505674A5 (cg-RX-API-DMAC7.html)
JP2023505492A5 (cg-RX-API-DMAC7.html)
JP2009225799A5 (cg-RX-API-DMAC7.html)
JP2005510246A5 (cg-RX-API-DMAC7.html)
JP2025183307A5 (cg-RX-API-DMAC7.html)
JP2010511388A5 (cg-RX-API-DMAC7.html)
JP2009532336A5 (cg-RX-API-DMAC7.html)
JP2008532949A5 (cg-RX-API-DMAC7.html)
JP2012522523A5 (cg-RX-API-DMAC7.html)
JP2014502955A5 (cg-RX-API-DMAC7.html)
JP2023545183A5 (cg-RX-API-DMAC7.html)
JP2020500834A5 (cg-RX-API-DMAC7.html)
JP2023018678A5 (cg-RX-API-DMAC7.html)
RU2010130994A (ru) Агенты против клетки-мишени, нацеленные на cd138, и их применение
JP2024086870A5 (cg-RX-API-DMAC7.html)